Skip to main content
SpringerLink
Log in

Liposomes in Drug Delivery

  • Chapter
  • First Online:
Book cover Fundamentals and Applications of Controlled Release Drug Delivery

Part of the book series: Advances in Delivery Science and Technology ((ADST))

Abstract

Liposomes, phospholipid bubbles with a bilayered membrane structure, are considered as promising pharmaceutical carriers for different applications. Currently, liposomes are used experimentally and clinically to deliver various pharmaceuticals including drugs and diagnostic agents as well as genes and related products. Research in the field of liposomes aims now at the development of various liposome-based multifunctional nanopreparations for therapy and diagnostics or for both simultaneously (theranostics). This chapter briefly addresses the basic properties of liposomes as drug delivery systems and the development and current status of some liposomal products.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ (2002) The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res 12:1–3

    PubMed  CAS  Google Scholar 

  2. Adamo V, Lorusso V, Rossello R, Adamo B, Ferraro G, Lorusso D, Condemi G, Priolo D, Di Lullo L, Paglia A, Pisconti S, Scambia G, Ferrandina G (2008) Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Br J Cancer 98:1916–1921

    PubMed  CAS  Google Scholar 

  3. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN (2005) Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 235:469–477

    PubMed  Google Scholar 

  4. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN (2005) Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 16:1365–1371

    PubMed  Google Scholar 

  5. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133–141

    PubMed  CAS  Google Scholar 

  6. Allen TM, Mumbengegwi DR, Charrois GJ (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11:3567–3573

    PubMed  CAS  Google Scholar 

  7. Allison AG, Gregoriadis G (1974) Liposomes as immunological adjuvants. Nature 252:252

    PubMed  CAS  Google Scholar 

  8. Asokan A, Cho MJ (2003) Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. Biochim Biophys Acta 1611:151–160

    PubMed  CAS  Google Scholar 

  9. Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H (2007) In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 30:972–978

    PubMed  CAS  Google Scholar 

  10. Audouy SA, de Leij LF, Hoekstra D, Molema G (2002) In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 19:1599–1605

    PubMed  CAS  Google Scholar 

  11. Awasthi VD, Garcia D, Klipper R, Goins BA, Phillips WT (2004) Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol)-distearoylphosphatidylethanolamine on distribution and circulation kinetics. J Pharmacol Exp Ther 309:241–248

    PubMed  CAS  Google Scholar 

  12. Babincova M, Altanerova V, Lampert M, Altaner C, Machova E, Sramka M, Babinec P (2000) Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field. Z Naturforsch C 55:278–281

    PubMed  CAS  Google Scholar 

  13. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58:700–703

    PubMed  CAS  Google Scholar 

  14. Balbi G, Visconti S, Monteverde A, Manganaro MA, Cardone A (2007) Liposomal doxorubicin: a phase II trial. Acta Biomed 78:210–213

    PubMed  CAS  Google Scholar 

  15. Bao A, Goins B, Klipper R, Negrete G, Mahindaratne M, Phillips WT (2003) A novel liposome radiolabeling method using 99mTc-"SNS/S" complexes: in vitro and in vivo evaluation. J Pharm Sci 92:1893–1904

    PubMed  CAS  Google Scholar 

  16. Bao A, Goins B, Klipper R, Negrete G, Phillips WT (2003) 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 44:1992–1999

    PubMed  CAS  Google Scholar 

  17. Bendsoe N, Persson L, Johansson A, Axelsson J, Svensson J, Grafe S, Trebst T, Andersson-Engels S, Svanberg S, Svanberg K (2007) Fluorescence monitoring of a topically applied liposomal Temoporfin formulation and photodynamic therapy of nonpigmented skin malignancies. J Environ Pathol Toxicol Oncol 26:117–126

    PubMed  CAS  Google Scholar 

  18. Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9:301–309

    PubMed  CAS  Google Scholar 

  19. Blume G, Cevc G (1993) Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta 1146:157–168

    PubMed  CAS  Google Scholar 

  20. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149:180–184

    PubMed  CAS  Google Scholar 

  21. Boddapati SV, D’Souza GG, Erdogan S, Torchilin VP, Weissig V (2008) Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559–2563

    PubMed  CAS  Google Scholar 

  22. Boddapati SV, Tongcharoensirikul P, Hanson RN, D’Souza GG, Torchilin VP, Weissig V (2005) Mitochondriotropic liposomes. J Liposome Res 15:49–58

    PubMed  CAS  Google Scholar 

  23. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM (2007) Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 30:655–662

    PubMed  CAS  Google Scholar 

  24. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN (2002) Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50:6–8

    PubMed  CAS  Google Scholar 

  25. Bourre L, Thibaut S, Fimiani M, Ferrand Y, Simonneaux G, Patrice T (2003) In vivo photosensitizing efficiency of a diphenylchlorin sensitizer: interest of a DMPC liposome formulation. Pharmacol Res 47:253–261

    PubMed  CAS  Google Scholar 

  26. Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F (2003) Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett 197:231–235

    PubMed  CAS  Google Scholar 

  27. Budai L, Hajdu M, Budai M, Grof P, Beni S, Noszal B, Klebovich I, Antal I (2007) Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm 343:34–40

    PubMed  CAS  Google Scholar 

  28. Cevc G (2004) Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 56:675–711

    PubMed  CAS  Google Scholar 

  29. Cevc G, Blume G (2001) New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta 1514:191–205

    PubMed  CAS  Google Scholar 

  30. Cevc G, Gebauer D (2003) Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. Biophys J 84:1010–1024

    PubMed  CAS  Google Scholar 

  31. Cevc G, Schatzlein A, Richardsen H (2002) Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 1564:21–30

    PubMed  CAS  Google Scholar 

  32. Chen B, Pogue BW, Hasan T (2005) Liposomal delivery of photosensitising agents. Expert Opin Drug Deliv 2:477–487

    PubMed  CAS  Google Scholar 

  33. Cheng WW, Allen TM (2008) Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 126:50–58

    PubMed  CAS  Google Scholar 

  34. Cheng WW, Das D, Suresh M, Allen TM (2007) Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta 1768:21–29

    PubMed  CAS  Google Scholar 

  35. Chikh G, Schutze-Redelmeier MP (2002) Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 22:339–353

    PubMed  CAS  Google Scholar 

  36. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP (2001) Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167:6462–6470

    PubMed  CAS  Google Scholar 

  37. Colley CM, Ryman BE (1976) The use of a liposomally entrapped enzyme in the treatment of an artificial storage condition. Biochim Biophys Acta 451:417–425

    PubMed  CAS  Google Scholar 

  38. Connor J, Huang L (1986) pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res 46:3431–3435

    PubMed  CAS  Google Scholar 

  39. Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W (2007) A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist 12:114–123

    PubMed  CAS  Google Scholar 

  40. Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM (2003) Liposomal delivery of antigen to human dendritic cells. Vaccine 21:883–890

    PubMed  CAS  Google Scholar 

  41. Crommelin DJ, Storm G (2003) Liposomes: from the bench to the bed. J Liposome Res 13:33–36

    PubMed  Google Scholar 

  42. D’Souza GG, Wang T, Rockwell K, Torchilin VP (2008) Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro. Pharm Res 25:2567–2572

    PubMed  Google Scholar 

  43. Dagar S, Rubinstein I, Onyuksel H (2003) Liposomes in ultrasound and gamma scintigraphic imaging. Methods Enzymol 373:198–214

    PubMed  CAS  Google Scholar 

  44. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA (2005) Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 23:1859–1866

    PubMed  CAS  Google Scholar 

  45. Deonarain MP, Epenetos AA (1994) Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer 70:786–794

    PubMed  CAS  Google Scholar 

  46. Derycke AS, De Witte PA (2002) Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int J Oncol 20:181–187

    PubMed  CAS  Google Scholar 

  47. Derycke AS, de Witte PA (2004) Liposomes for photodynamic therapy. Adv Drug Deliv Rev 56:17–30

    PubMed  CAS  Google Scholar 

  48. Desai TR, Hancock RE, Finlay WH (2002) A facile method of delivery of liposomes by nebulization. J Control Release 84:69–78

    PubMed  CAS  Google Scholar 

  49. Desnick RJ, Thorpe SR, Fiddler MB (1976) Toward enzyme therapy for lysosomal storage diseases. Physiol Rev 56:57–99

    PubMed  CAS  Google Scholar 

  50. Diebold Y, Jarrin M, Saez V, Carvalho EL, Orea M, Calonge M, Seijo B, Alonso MJ (2007) Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553–1564

    PubMed  CAS  Google Scholar 

  51. Ding WX, Qi XR, Fu Q, Piao HS (2007) Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. Drug Deliv 14:101–104

    PubMed  CAS  Google Scholar 

  52. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A (2006) A phase 2 trial of the liposomal DACH platinum l-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 58:759–764

    PubMed  CAS  Google Scholar 

  53. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, Wood BJ (2007) Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 13:2722–2727

    PubMed  CAS  Google Scholar 

  54. du Plessis J, Egbaria K, Ramachandran C, Weiner N (1992) Topical delivery of liposomally encapsulated gamma-interferon. Antiviral Res 18:259–265

    PubMed  Google Scholar 

  55. Egbaria K, Ramachandran C, Kittayanond D, Weiner N (1990) Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob Agents Chemother 34:107–110

    PubMed  CAS  Google Scholar 

  56. Egbaria K, Ramachandran C, Weiner N (1990) Topical delivery of ciclosporin: evaluation of various formulations using in vitro diffusion studies in hairless mouse skin. Skin Pharmacol 3:21–28

    PubMed  CAS  Google Scholar 

  57. el Guink N, Kris RM, Goodman-Snitkoff G, Small PA Jr, Mannino RJ (1989) Intranasal immunization with proteoliposomes protects against influenza. Vaccine 7:147–151

    PubMed  CAS  Google Scholar 

  58. Elbayoumi TA, Torchilin VP (2006) Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging 33:1196–1205

    PubMed  CAS  Google Scholar 

  59. Elbayoumi TA, Torchilin VP (2007) Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci 32:159–168

    PubMed  CAS  Google Scholar 

  60. Elbayoumi TA, Torchilin VP (2008) Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 5:1185–1198

    PubMed  CAS  Google Scholar 

  61. Elbayoumi TA, Torchilin VP (2008) Tumor-specific antibody-mediated targeted delivery of Doxil((R)) reduces the manifestation of auricular erythema side effect in mice. Int J Pharm 357:272–279

    PubMed  CAS  Google Scholar 

  62. Elbayoumi TA, Torchilin VP (2009) Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol Pharm 6:246–254

    PubMed  CAS  Google Scholar 

  63. ElBayoumi TA, Torchilin VP (2009) Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973–1980

    PubMed  CAS  Google Scholar 

  64. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM (2006) Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm 322:60–66

    PubMed  CAS  Google Scholar 

  65. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM (2007) Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie 62:133–137

    PubMed  CAS  Google Scholar 

  66. Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VP (2008) Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J Magn Reson Imaging 27:574–580

    PubMed  Google Scholar 

  67. Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP (2006) Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J Liposome Res 16:45–55

    PubMed  CAS  Google Scholar 

  68. Erdogan S, Roby A, Torchilin VP (2006) Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. Mol Pharm 3:525–530

    PubMed  CAS  Google Scholar 

  69. Fattal E, Couvreur P, Dubernet C (2004) "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 56:931–946

    PubMed  CAS  Google Scholar 

  70. Felgner PL, Ringold GM (1989) Cationic liposome-mediated transfection. Nature 337:387–388

    PubMed  CAS  Google Scholar 

  71. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890–896

    PubMed  CAS  Google Scholar 

  72. Fishman Y, Citri N (1975) l-asparaginase entrapped in liposomes: preparation and properties. FEBS Lett 60:17–20

    PubMed  CAS  Google Scholar 

  73. Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C, Weiner N (1995) Topical delivery of growth hormone releasing peptide using liposomal systems: an in vitro study using hairless mouse skin. Life Sci 57:1293–1297

    PubMed  CAS  Google Scholar 

  74. Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G (2003) Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm Res 20:423–428

    PubMed  CAS  Google Scholar 

  75. Freeman BA, Turrens JF, Mirza Z, Crapo JD, Young SL (1985) Modulation of oxidant lung injury by using liposome-entrapped superoxide dismutase and catalase. Fed Proc 44:2591–2595

    PubMed  CAS  Google Scholar 

  76. Freeman BA, Young SL, Crapo JD (1983) Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem 258:12534–12542

    PubMed  CAS  Google Scholar 

  77. Friede M (1995) Liposomes as carriers of antigens. In: Philippot JR, Schuber F (eds) Liposomes as tools in basic research and industry. CRC, Boca Raton, pp 189–200

    Google Scholar 

  78. Fujimoto Y, Okuhata Y, Tyngi S, Namba Y, Oku N (2000) Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. Biol Pharm Bull 23:97–100

    PubMed  CAS  Google Scholar 

  79. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–1192

    PubMed  CAS  Google Scholar 

  80. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424–436

    PubMed  CAS  Google Scholar 

  81. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, de Witte P (2002) Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 101:78–85

    PubMed  CAS  Google Scholar 

  82. Gilbert BE, Seryshev A, Knight V, Brayton C (2002) 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185–197

    PubMed  CAS  Google Scholar 

  83. Goncalves A, Braud AC, Viret F, Genre D, Gravis G, Tarpin C, Giovannini M, Maraninchi D, Viens P (2003) Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res 23:3543–3548

    PubMed  CAS  Google Scholar 

  84. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO (2006) Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 16:521–526

    PubMed  CAS  Google Scholar 

  85. Gorodetsky R, Levdansky L, Vexler A, Shimeliovich I, Kassis I, Ben-Moshe M, Magdassi S, Marx G (2004) Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. J Control Release 95:477–488

    PubMed  CAS  Google Scholar 

  86. Grabowsky GA, Desnick RJ (1981) Enzyme replacement in genetic diseases. In: Holcenberg JS, Roberts J (eds) Enzymes as drugs. Wiley, New York, p 167

    Google Scholar 

  87. Grant GJ, Barenholz Y, Bolotin EM, Bansinath M, Turndorf H, Piskoun B, Davidson EM (2004) A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 101:133–137

    PubMed  CAS  Google Scholar 

  88. Gregoriadis G (1978) Liposomes in the therapy of lysosomal storage diseases. Nature 275:695–696

    PubMed  CAS  Google Scholar 

  89. Gregoriadis G (1993) Liposomes as immunological adjuvants for peptide and protein antigens. In: Gregoriadis G, Florence AT, Patel HM (eds) Liposomes in drug delivery. Harwood Academic Publishers, Switzerland, pp 77–94

    Google Scholar 

  90. Gregoriadis G (2007) Liposome technology: Liposome preparation and related techniques, 3rd edn., 1–3. Informa Healthcare, New York, p 1240

    Google Scholar 

  91. Gregoriadis G, Dean MF (1979) Enzyme therapy in genetic diseases. Nature 278:603–604

    PubMed  CAS  Google Scholar 

  92. Gregoriadis G, Putman D, Louis L, Neerunjun D (1974) Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. Biochem J 140:323–330

    PubMed  CAS  Google Scholar 

  93. Gregoriadis G, Ryman BE (1972) Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats. Biochem J 129:123–133

    PubMed  CAS  Google Scholar 

  94. Griffiths GD, Phillips GJ, Bailey SC (1999) Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 17:2562–2568

    PubMed  CAS  Google Scholar 

  95. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Alfaro RM, King C, Piscitelli SC, Walsh TJ (2003) Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob Agents Chemother 47:3917–3925

    PubMed  CAS  Google Scholar 

  96. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, Longenecker BM, Samuel J (1998) Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 9:451–458

    PubMed  CAS  Google Scholar 

  97. Gupta B, Levchenko TS, Torchilin VP (2007) TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 16:351–359

    PubMed  Google Scholar 

  98. Gupta B, Torchilin VP (2007) Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 56:1215–1223

    PubMed  CAS  Google Scholar 

  99. Gupta Y, Jain A, Jain P, Jain SK (2007) Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J Drug Target 15:231–240

    PubMed  CAS  Google Scholar 

  100. Han YY, Huang L, Jackson EK, Dubey RK, Gillepsie DG, Carcillo JA (2001) Liposomal atp or NAD+ protects human endothelial cells from energy failure in a cell culture model of sepsis. Res Commun Mol Pathol Pharmacol 110:107–116

    PubMed  CAS  Google Scholar 

  101. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1239:133–144

    PubMed  Google Scholar 

  102. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37:2015–2022

    PubMed  CAS  Google Scholar 

  103. Hartner WC, Verma DD, Levchenko TS, Bernstein EA, Torchilin VP (2009) ATP-loaded liposomes for treatment of myocardial ischemia. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:530–539

    PubMed  CAS  Google Scholar 

  104. Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H (2007) Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 342:194–200

    PubMed  CAS  Google Scholar 

  105. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H (2004) Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 281:25–33

    PubMed  CAS  Google Scholar 

  106. Hathout RM, Mansour S, Mortada ND, Guinedi AS (2007) Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 8:1

    PubMed  Google Scholar 

  107. Hayward JA, Levine DM, Neufeld L, Simon SR, Johnston DS, Chapman D (1985) Polymerized liposomes as stable oxygen-carriers. FEBS Lett 187:261–266

    PubMed  CAS  Google Scholar 

  108. Heath TD, Shek P, Papahadjopoulos D (1986) Production of immunogens by antigen conjugation to liposomes. The Regents of the University of California, United States

    Google Scholar 

  109. Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, Kluft C, Crommelin DJ (1995) Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb Haemost 73:488–494

    PubMed  CAS  Google Scholar 

  110. Honeywell-Nguyen PL, Frederik PM, Bomans PHH, Junginger HE, Bouwstra JA (2002) Transdermal delivery of pergolide from surfactant-based elastic and rigid vesicles: characterization and in vitro transport studies. Pharmaceut Res (NY) 19:991–997

    CAS  Google Scholar 

  111. Hudson LD, Fiddler MB, Desnick RJ (1979) Enzyme therapy. X. Immune response induced by enzyme- and buffer-loaded liposomes in C3H/HeJ Gus(h) mice. J Pharmacol Exp Ther 208:507–514

    PubMed  CAS  Google Scholar 

  112. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93:14164–14169

    PubMed  CAS  Google Scholar 

  113. Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, Oku N (2004) Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett 205:39–48

    PubMed  CAS  Google Scholar 

  114. Igarashi A, Konno H, Tanaka T, Nakamura S, Sadzuka Y, Hirano T, Fujise Y (2003) Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer. Toxicol Lett 145:133–141

    PubMed  CAS  Google Scholar 

  115. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99:130–137

    PubMed  CAS  Google Scholar 

  116. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18:1042–1048

    PubMed  CAS  Google Scholar 

  117. Iwanaga K, Ono S, Narioka K, Kakemi M, Morimoto K, Yamashita S, Namba Y, Oku N (1999) Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome’s surface on the GI transit of insulin. J Pharm Sci 88:248–252

    PubMed  CAS  Google Scholar 

  118. Jayanna PK, Torchilin VP, Petrenko VA (2009) Liposomes targeted by fusion phage proteins. Nanomedicine 5:83–89

    PubMed  CAS  Google Scholar 

  119. Jehn CF, Boulikas T, Kourvetaris A, Possinger K, Luftner D (2007) Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 27:471–475

    PubMed  CAS  Google Scholar 

  120. Jezek P, Nekvasil M, Skobisova E, Urbankova E, Jirsa M, Zadinova M, Pouckova P, Klepacek I (2003) Experimental photodynamic therapy with MESO-tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice. Int J Cancer 103:693–702

    PubMed  CAS  Google Scholar 

  121. Johnston SR, Gore ME (2001) Caelyx: phase II studies in ovarian cancer. Eur J Cancer 37(Suppl 9):S8–S14

    PubMed  CAS  Google Scholar 

  122. Jorge JC, Perez-Soler R, Morais JG, Cruz ME (1994) Liposomal palmitoyl-l-asparaginase: characterization and biological activity. Cancer Chemother Pharmacol 34:230–234

    PubMed  CAS  Google Scholar 

  123. Joshee N, Bastola DR, Cheng PW (2002) Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum Gene Ther 13:1991–2004

    PubMed  CAS  Google Scholar 

  124. Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T, Maruyama K, Kamiya H, Harashima H (2004) Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43:5618–5628

    PubMed  CAS  Google Scholar 

  125. Kale AA, Torchilin VP (2007) Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug Chem 18:363–370

    PubMed  CAS  Google Scholar 

  126. Kale AA, Torchilin VP (2007) Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target 15:538–545

    PubMed  CAS  Google Scholar 

  127. Kamps JA, Koning GA, Velinova MJ, Morselt HW, Wilkens M, Gorter A, Donga J, Scherphof GL (2000) Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J Drug Target 8:235–245

    PubMed  CAS  Google Scholar 

  128. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K (2001) A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol 53:295–302

    PubMed  CAS  Google Scholar 

  129. Karanth H, Murthy RS (2007) pH-sensitive liposomes–principle and application in cancer therapy. J Pharm Pharmacol 59:469–483

    PubMed  CAS  Google Scholar 

  130. Kato A, Tanaka I, Arakawa M, Kondo T (1985) Liposome-type artificial red blood cells stabilized with carboxymethyl chitin. Biomater Med Devices Artif Organs 13:61–82

    PubMed  CAS  Google Scholar 

  131. Kedar E, Palgi O, Golod G, Babai I, Barenholz Y (1997) Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother 20:180–193

    PubMed  CAS  Google Scholar 

  132. Kessner S, Krause A, Rothe U, Bendas G (2001) Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells. Biochim Biophys Acta 1514:177–190

    PubMed  CAS  Google Scholar 

  133. Khaw BA, daSilva J, Vural I, Narula J, Torchilin VP (2001) Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Control Release 75:199–210

    PubMed  CAS  Google Scholar 

  134. Khaw BA, Torchilin VP, Vural I, Narula J (1995) Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1:1195–1198

    PubMed  CAS  Google Scholar 

  135. Kheirolomoom A, Dayton PA, Lum AF, Little E, Paoli EE, Zheng H, Ferrara KW (2007) Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J Control Release 118:275–284

    PubMed  CAS  Google Scholar 

  136. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen C, Apparailly F (2006) Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54:1867–1877

    PubMed  CAS  Google Scholar 

  137. Kim CK, Han JH (1995) Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 12:437–446

    PubMed  CAS  Google Scholar 

  138. Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS (2001) A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34:427–432

    PubMed  CAS  Google Scholar 

  139. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66–75

    PubMed  CAS  Google Scholar 

  140. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732–6740

    PubMed  CAS  Google Scholar 

  141. Kisel MA, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob’yov MS, Kholodova EA, Zabarovskaya ZV (2001) Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm 216:105–114

    PubMed  CAS  Google Scholar 

  142. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N (1995) Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18:93–99

    PubMed  CAS  Google Scholar 

  143. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235–237

    PubMed  CAS  Google Scholar 

  144. Klibanov AL, Torchilin VP, Zalipsky S (2003) Long-circulating sterically protected liposomes. In: Torchilin VP, Weissig V (eds) Liposomes: a practical approach, 2nd edn. Oxford University Press, New York, pp 231–265

    Google Scholar 

  145. Konduri KS, Nandedkar S, Duzgunes N, Suzara V, Artwohl J, Bunte R, Gangadharam PR (2003) Efficacy of liposomal budesonide in experimental asthma. J Allergy Clin Immunol 111:321–327

    PubMed  CAS  Google Scholar 

  146. Koning GA, Gorter A, Scherphof GL, Kamps JA (1999) Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br J Cancer 80:1718–1725

    PubMed  CAS  Google Scholar 

  147. Konno H, Matin AF, Maruo Y, Nakamura S, Baba S (1996) Liposomal ATP protects the liver from injury during shock. Eur Surg Res 28:140–145

    PubMed  CAS  Google Scholar 

  148. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V (2004) Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 17:7–14

    PubMed  CAS  Google Scholar 

  149. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V (2000) 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876–2880

    PubMed  CAS  Google Scholar 

  150. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T (2001) Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 18:121–125

    PubMed  CAS  Google Scholar 

  151. Laham A, Claperon N, Durussel JJ, Fattal E, Delattre J, Puisieux F, Couvreur P, Rossignol P (1988) Liposomally entrapped adenosine triphosphate. Improved efficiency against experimental brain ischaemia in the rat. J Chromatogr 440:455–458

    PubMed  CAS  Google Scholar 

  152. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK (2006) Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5:1708–1713

    PubMed  CAS  Google Scholar 

  153. Lange CF, Hancock RE, Samuel J, Finlay WH (2001) In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci 90:1647–1657

    PubMed  CAS  Google Scholar 

  154. Lanternier F, Lortholary O (2008) Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 14(Suppl 4):71–83

    PubMed  CAS  Google Scholar 

  155. Lasic DD, Martin FJ (1995) Stealth liposomes. CRC, Boca Raton, p 320

    Google Scholar 

  156. Lasic DD, Papahadjopoulos D (1998) Medical applications of liposomes. Elsevier, Amsterdam, p xiv, 79

    Google Scholar 

  157. Lasic DD, Vallner JJ, Working PK (1999) Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther 1:177–185

    PubMed  CAS  Google Scholar 

  158. Law SL, Shih CL (2001) Characterization of calcitonin-containing liposome formulations for intranasal delivery. J Microencapsul 18:211–221

    PubMed  CAS  Google Scholar 

  159. Leamon CP, Cooper SR, Hardee GE (2003) Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14:738–747

    PubMed  CAS  Google Scholar 

  160. Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88:5572–5576

    PubMed  CAS  Google Scholar 

  161. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M (2002) Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62:4282–4288

    PubMed  CAS  Google Scholar 

  162. Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198–3204

    PubMed  CAS  Google Scholar 

  163. Li H, Song JH, Park JS, Han K (2003) Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm 258:11–19

    PubMed  CAS  Google Scholar 

  164. Liang W, Levchenko T, Khaw BA, Torchilin V (2004) ATP-containing immunoliposomes specific for cardiac myosin. Curr Drug Deliv 1:1–7

    PubMed  CAS  Google Scholar 

  165. Lo YL, Tsai JC, Kuo JH (2004) Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release 94:259–272

    PubMed  CAS  Google Scholar 

  166. Lokling KE, Fossheim SL, Klaveness J, Skurtveit R (2004) Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. J Control Release 98:87–95

    PubMed  CAS  Google Scholar 

  167. Lopes de Menezes DE, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320–3330

    PubMed  CAS  Google Scholar 

  168. Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM (2000) Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 1466:205–220

    PubMed  CAS  Google Scholar 

  169. Lu Y, Low PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675–693

    PubMed  CAS  Google Scholar 

  170. Lu Y, Low PS (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51:153–162

    PubMed  CAS  Google Scholar 

  171. Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM, Hengartner H, Schwendener RA (2000) In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19:23–32

    PubMed  CAS  Google Scholar 

  172. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP (2004) Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 100:135–144

    PubMed  CAS  Google Scholar 

  173. Lundberg BB, Griffiths G, Hansen HJ (2007) Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Deliv 14:171–175

    PubMed  CAS  Google Scholar 

  174. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS (1985) Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817:67–74

    PubMed  CAS  Google Scholar 

  175. Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61

    PubMed  CAS  Google Scholar 

  176. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63:3154–3161

    PubMed  CAS  Google Scholar 

  177. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65:11631–11638

    PubMed  CAS  Google Scholar 

  178. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF (2006) EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target 14:215–223

    PubMed  CAS  Google Scholar 

  179. Manesis EK, Cameron CH, Gregoriadis G (1979) Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. FEBS Lett 102:107–111

    PubMed  CAS  Google Scholar 

  180. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA (2002) Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 87:106–112

    PubMed  CAS  Google Scholar 

  181. Maruyama K (2000) In vivo targeting by liposomes. Biol Pharm Bull 23:791–799

    PubMed  CAS  Google Scholar 

  182. Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G (2002) Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 277:27135–27143

    PubMed  CAS  Google Scholar 

  183. Masuda K, Horie K, Suzuki R, Yoshikawa T, Hirano K (2002) Oral delivery of antigens in liposomes with some lipid compositions modulates oral tolerance to the antigens. Microbiol Immunol 46:55–58

    PubMed  CAS  Google Scholar 

  184. Matsuura M, Yamazaki Y, Sugiyama M, Kondo M, Ori H, Nango M, Oku N (2003) Polycation liposome-mediated gene transfer in vivo. Biochim Biophys Acta 1612:136–143

    PubMed  CAS  Google Scholar 

  185. Metselaar JM, Bruin P, de Boer LW, de Vringer T, Snel C, Oussoren C, Wauben MH, Crommelin DJ, Storm G, Hennink WE (2003) A novel family of l-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156–1164

    PubMed  CAS  Google Scholar 

  186. Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N (2003) Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 89:189–197

    PubMed  CAS  Google Scholar 

  187. Moein Moghimi S, Hamad I, Bunger R, Andresen TL, Jorgensen K, Hunter AC, Baranji L, Rosivall L, Szebeni J (2006) Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16:167–174

    PubMed  CAS  Google Scholar 

  188. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463–478

    PubMed  CAS  Google Scholar 

  189. Nam SM, Kim HS, Ahn WS, Park YS (1999) Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Oncol Res 11:9–16

    PubMed  CAS  Google Scholar 

  190. Naoi M, Yagi K (1980) Incorporation of enzyme through blood-brainbarrier into the brain by means of liposomes. Biochem Int 1:591–596

    CAS  Google Scholar 

  191. Neveux N, De Bandt JP, Chaumeil JC, Cynober L (2002) Hepatic preservation, liposomally entrapped adenosine triphosphate and nitric oxide production: a study of energy state and protein metabolism in the cold-stored rat liver. Scand J Gastroenterol 37:1057–1063

    PubMed  CAS  Google Scholar 

  192. Ni S, Stephenson SM, Lee RJ (2002) Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22:2131–2135

    PubMed  CAS  Google Scholar 

  193. Niibori K, Wroblewski KP, Yokoyama H, Crestanello JA, Whitman GJ (1999) Bioenergetic effect of liposomal coenzyme Q10 on myocardial ischemia reperfusion injury. Biofactors 9:307–313

    PubMed  CAS  Google Scholar 

  194. Nobuto H, Sugita T, Kubo T, Shimose S, Yasunaga Y, Murakami T, Ochi M (2004) Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer 109:627–635

    PubMed  CAS  Google Scholar 

  195. O’Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4:318–328

    PubMed  Google Scholar 

  196. Omori N, Maruyama K, Jin G, Li F, Wang SJ, Hamakawa Y, Sato K, Nagano I, Shoji M, Abe K (2003) Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 25:275–279

    PubMed  CAS  Google Scholar 

  197. Opanasopit P, Sakai M, Nishikawa M, Kawakami S, Yamashita F, Hashida M (2002) Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release 80:283–294

    PubMed  CAS  Google Scholar 

  198. Oussoren C, Storm G (2001) Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50:143–156

    PubMed  CAS  Google Scholar 

  199. Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M (1999) GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 81:268–274

    PubMed  CAS  Google Scholar 

  200. Pan H, Han L, Chen W, Yao M, Lu W (2008) Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release 125:228–235

    PubMed  CAS  Google Scholar 

  201. Pan XQ, Wang H, Lee RJ (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20:417–422

    PubMed  CAS  Google Scholar 

  202. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594–602

    PubMed  CAS  Google Scholar 

  203. Pappalardo JS, Quattrocchi V, Langellotti C, Di Giacomo S, Gnazzo V, Olivera V, Calamante G, Zamorano PI, Levchenko TS, Torchilin VP (2009) Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes. J Control Release 134:41–46

    PubMed  CAS  Google Scholar 

  204. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181

    PubMed  CAS  Google Scholar 

  205. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95–113

    PubMed  CAS  Google Scholar 

  206. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M (2003) Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86–92

    PubMed  CAS  Google Scholar 

  207. Patel HM, Ryman BE (1974) α-Mannosidase in zinc-deficient rats. Possibility of liposomal therapy in mannosidosis. Biochem Soc Trans 2:1014–1017

    CAS  Google Scholar 

  208. Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D’Souza GG (2010) Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res 20(3):244–249

    PubMed  CAS  Google Scholar 

  209. Peer D, Margalit R (2004) Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108:780–789

    PubMed  CAS  Google Scholar 

  210. Perez-Lopez ME, Curiel T, Gomez JG, Jorge M (2007) Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18:611–617

    PubMed  CAS  Google Scholar 

  211. Perez AT, Domenech GH, Frankel C, Vogel CL (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 20(Suppl 2):22–29

    PubMed  CAS  Google Scholar 

  212. Phillips WT, Klipper RW, Awasthi VD, Rudolph AS, Cliff R, Kwasiborski V, Goins BA (1999) Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J Pharmacol Exp Ther 288:665–670

    PubMed  CAS  Google Scholar 

  213. Plassat V, Martina MS, Barratt G, Menager C, Lesieur S (2007) Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. Int J Pharm 344:118–127

    PubMed  CAS  Google Scholar 

  214. Postma NS, Crommelin DJ, Eling WM, Zuidema J (1999) Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. J Pharmacol Exp Ther 288:114–120

    PubMed  CAS  Google Scholar 

  215. Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Bogenmann E, Ponzoni M, Montaldo PG (2003) Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett 197:151–155

    PubMed  CAS  Google Scholar 

  216. Rao M, Alving CR (2000) Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv Drug Deliv Rev 41:171–188

    PubMed  CAS  Google Scholar 

  217. Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP (2002) Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 9:1542–1550

    PubMed  CAS  Google Scholar 

  218. Reynolds GC, Baker HJ, Reynolds RH (1978) Enzyme replacement using liposome carriers in feline Gm1 gangliosidosis fibroblasts. Nature 275:754–755

    PubMed  CAS  Google Scholar 

  219. Rogers JA, Anderson KE (1998) The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carrier Syst 15:421–480

    PubMed  CAS  Google Scholar 

  220. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA (2004) Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 126:9506–9507

    PubMed  CAS  Google Scholar 

  221. Roux E, Passirani C, Scheffold S, Benoit JP, Leroux JC (2004) Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J Control Release 94:447–451

    PubMed  CAS  Google Scholar 

  222. Ruozi B, Battini R, Montanari M, Mucci A, Tosi G, Forni F, Vandelli MA (2007) DOTAP/UDCA vesicles: novel approach in oligonucleotide delivery. Nanomedicine 3:1–13

    PubMed  CAS  Google Scholar 

  223. Sachse A, Leike JU, Rossling GL, Wagner SE, Krause W (1993) Preparation and evaluation of lyophilized iopromide-carrying liposomes for liver tumor detection. Invest Radiol 28:838–844

    PubMed  CAS  Google Scholar 

  224. Sachse A, Leike JU, Schneider T, Wagner SE, Rossling GL, Krause W, Brandl M (1997) Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes. Invest Radiol 32:44–50

    PubMed  CAS  Google Scholar 

  225. Safinya CR (2001) Structures of lipid-DNA complexes: supramolecular assembly and gene delivery. Curr Opin Struct Biol 11:440–448

    PubMed  CAS  Google Scholar 

  226. Sakai H, Masada Y, Horinouchi H, Yamamoto M, Ikeda E, Takeoka S, Kobayashi K, Tsuchida E (2004) Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med 32:539–545

    PubMed  CAS  Google Scholar 

  227. Sakai H, Tomiyama KI, Sou K, Takeoka S, Tsuchida E (2000) Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug Chem 11:425–432

    PubMed  CAS  Google Scholar 

  228. Sakai H, Tsai AG, Rohlfs RJ, Hara H, Takeoka S, Tsuchida E, Intaglietta M (1999) Microvascular responses to hemodilution with Hb vesicles as red blood cell substitutes: influence of O2 affinity. Am J Physiol 276:H553–H562

    PubMed  CAS  Google Scholar 

  229. Sanchez Y, Ionescu-Matiu I, Dreesman GR, Kramp W, Six HR, Hollinger FB, Melnick JL (1980) Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant alum, and liposomes. Infect Immun 30:728–733

    PubMed  CAS  Google Scholar 

  230. Sangha R, Butts C (2007) L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 13:s4652–s4654

    PubMed  Google Scholar 

  231. Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62:7190–7194

    PubMed  CAS  Google Scholar 

  232. Sapra P, Allen TM (2004) Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 10:2530–2537

    PubMed  CAS  Google Scholar 

  233. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F (2000) Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing phase II trial. Ann Oncol 11:69–72

    PubMed  CAS  Google Scholar 

  234. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M (2007) Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28:1434–1442

    PubMed  CAS  Google Scholar 

  235. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP (2006) "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17:943–949

    PubMed  CAS  Google Scholar 

  236. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115–122

    PubMed  CAS  Google Scholar 

  237. Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85:1850–1852

    PubMed  CAS  Google Scholar 

  238. Schnyder A, Krahenbuhl S, Drewe J, Huwyler J (2005) Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 13:325–335

    PubMed  CAS  Google Scholar 

  239. Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y (2007) Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir 23:4019–4025

    PubMed  CAS  Google Scholar 

  240. Schwonzen M, Kurbacher CM, Mallmann P (2000) Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 11:681–685

    PubMed  CAS  Google Scholar 

  241. Scott RC, Wang B, Nallamothu R, Pattillo CB, Perez-Liz G, Issekutz A, Valle LD, Wood GC, Kiani MF (2007) Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 96:795–802

    PubMed  CAS  Google Scholar 

  242. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E (2004) A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 93:229–232

    PubMed  CAS  Google Scholar 

  243. Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, Banerjee A (1999) Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res 84:867–875

    PubMed  CAS  Google Scholar 

  244. Senior JH (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3:123–193

    PubMed  CAS  Google Scholar 

  245. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A 85:4842–4846

    PubMed  CAS  Google Scholar 

  246. Shibuya-Fujiwara N, Hirayama F, Ogata Y, Ikeda H, Ikebuchi K (2001) Phagocytosis in vitro of polyethylene glycol-modified liposome-encapsulated hemoglobin by human peripheral blood monocytes plus macrophages through scavenger receptors. Life Sci 70:291–300

    PubMed  CAS  Google Scholar 

  247. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56:947–965

    PubMed  CAS  Google Scholar 

  248. Sinha RK, Khuller GK (1997) The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra against tuberculosis in mice. Immunol Cell Biol 75:461–466

    PubMed  CAS  Google Scholar 

  249. Sioud M, Sorensen DR (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312:1220–1225

    PubMed  CAS  Google Scholar 

  250. Skubitz KM (2003) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 21:167–176

    PubMed  CAS  Google Scholar 

  251. Sofou S (2007) Surface-active liposomes for targeted cancer therapy. Nanomed 2:711–724

    CAS  Google Scholar 

  252. Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 5:189–204

    PubMed  CAS  Google Scholar 

  253. Stanimirovic DB, Markovic M, Micic DV, Spatz M, Mrsulja BB (1994) Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion ‘oxidative stress’ in gerbil brain. Neurochem Res 19:1473–1478

    PubMed  CAS  Google Scholar 

  254. Steele G Jr, Ravikumar T, Ross D, King V, Wilson RE, Dodson T (1984) Specific active immunotherapy with butanol-extracted, tumor-associated antigens incorporated into liposomes. Surgery 96:352–359

    PubMed  Google Scholar 

  255. Steger LD, Desnick RJ (1977) Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim Biophys Acta 464:530–546

    PubMed  CAS  Google Scholar 

  256. Stephenson SM, Yang W, Stevens PJ, Tjarks W, Barth RF, Lee RJ (2003) Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res 23:3341–3345

    PubMed  CAS  Google Scholar 

  257. Storm G, Vingerhoeds MH, Crommelin DJA, Haisma HJ (1997) Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Adv Drug Del Rev 24:225–231, 227

    CAS  Google Scholar 

  258. Sudimack JJ, Guo W, Tjarks W, Lee RJ (2002) A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 1564:31–37

    PubMed  CAS  Google Scholar 

  259. Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB (2000) Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60:6942–6949

    PubMed  CAS  Google Scholar 

  260. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37:800–804

    PubMed  CAS  Google Scholar 

  261. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72–78

    PubMed  CAS  Google Scholar 

  262. Szebeni J, Alving CR (1999) Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 27:23–41

    PubMed  CAS  Google Scholar 

  263. Szebeni J, Di Iorio EE, Hauser H, Winterhalter KH (1985) Encapsulation of hemoglobin in phospholipid liposomes: characterization and stability. Biochemistry 24:2827–2832

    PubMed  CAS  Google Scholar 

  264. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, Stahl GL, Bunger R, Alving CR (1999) Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99:2302–2309

    PubMed  CAS  Google Scholar 

  265. Szoka F Jr, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9:467–508

    PubMed  CAS  Google Scholar 

  266. Taira MC, Chiaramoni NS, Pecuch KM, Alonso-Romanowski S (2004) Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv 11:123–128

    PubMed  CAS  Google Scholar 

  267. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y (2001) Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75:83–91

    PubMed  CAS  Google Scholar 

  268. Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39–54

    PubMed  CAS  Google Scholar 

  269. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1996) Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 13:896–901

    PubMed  CAS  Google Scholar 

  270. Takeuchi Y, Ichikawa K, Yonezawa S, Kurohane K, Koishi T, Nango M, Namba Y, Oku N (2004) Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J Control Release 97:231–240

    PubMed  CAS  Google Scholar 

  271. Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DF, Haskard DO, Taylor KM, George AJ (2003) Antibody targeted gene transfer to endothelium. J Gene Med 5:311–323

    PubMed  CAS  Google Scholar 

  272. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L (2009) In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33:129–139

    PubMed  CAS  Google Scholar 

  273. Templeton NS (2002) Cationic liposome-mediated gene delivery in vivo. Biosci Rep 22:283–295

    PubMed  CAS  Google Scholar 

  274. Terada T, Mizobata M, Kawakami S, Yamashita F, Hashida M (2007) Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release 119:262–270

    PubMed  CAS  Google Scholar 

  275. Tilcock C (1995) Imaging tools: liposomal agents for nuclear medicine, computed tomography, magnetic resonance, and ultrasound. In: Philippot JR, Schuber F (eds) Liposomes as tools in basic research and industry. CRC, Boca Raton, pp 225–240

    Google Scholar 

  276. Torchilin V (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5:1003–1025

    PubMed  CAS  Google Scholar 

  277. Torchilin VP (1985) Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 2:65–115

    PubMed  CAS  Google Scholar 

  278. Torchilin VP (1996) Liposomes as delivery agents for medical imaging. Mol Med Today 2:242–249

    PubMed  CAS  Google Scholar 

  279. Torchilin VP (1997) Surface-modified liposomes in gamma- and MR-imaging. Adv Drug Deliv Rev 24:301–313

    CAS  Google Scholar 

  280. Torchilin VP (2000) Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 1:183–215

    PubMed  CAS  Google Scholar 

  281. Torchilin VP (2005) Liposomal delivery of protein and peptide drugs. In: Mahato RI (ed) Biomaterials for delivery and targeting of proteins and nucleic acids, chapter 14. CRC, Boca Raton, pp 433–459

    Google Scholar 

  282. Torchilin VP, Klibanov AL, Huang L, O’Donnell S, Nossiff ND, Khaw BA (1992) Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 6:2716–2719

    PubMed  CAS  Google Scholar 

  283. Torchilin VP, Levchenko TS (2003) TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci 4:133–140

    PubMed  CAS  Google Scholar 

  284. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR (2001) p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 1511:397–411

    PubMed  CAS  Google Scholar 

  285. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D’Souza GG (2003) Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A 100:1972–1977

    PubMed  CAS  Google Scholar 

  286. Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI (2001) Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 22:3035–3044

    PubMed  CAS  Google Scholar 

  287. Torchilin VP, Rammohan R, Weissig V, Levchenko TS (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 98:8786–8791

    PubMed  CAS  Google Scholar 

  288. Torchilin VP, Trubetskoy VS (1995) Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 16:141–155

    CAS  Google Scholar 

  289. Torchilin VP, Weissig V (2003) Liposomes: a practical approach. Practical approach series; 264, 2nd edn. Oxford University Press, New York, p xxiii

    Google Scholar 

  290. Torchilin VP, Weissig V, Martin FJ, Heath TD, Ne RRC (2003) Surface modifications of liposomes. In: Torchilin VP, Weissig V (eds) Liposomes: a practical approach, 2nd edn. Oxford University Press, New York, pp 193–229

    Google Scholar 

  291. Trudel M, Nadon F (1981) Virosome preparation: differences between influenza and rubella hemagglutinin adsorption. Can J Microbiol 27:958–962

    PubMed  CAS  Google Scholar 

  292. Tseng YL, Hong RL, Tao MH, Chang FH (1999) Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer 80:723–730

    PubMed  CAS  Google Scholar 

  293. Tseng YL, Liu JJ, Hong RL (2002) Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 62:864–872

    PubMed  CAS  Google Scholar 

  294. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O’Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E (2006) Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M D. Anderson Cancer Center Series. Leuk Lymphoma 47:1062–1068

    PubMed  CAS  Google Scholar 

  295. Tsuchida E, Hasegawa E, Matsushita Y, Eshima K, Yuasa M, Nishide H (1985) Polymerized liposome as the carrier of heme. A physically stable oxygen carrier under physiological conditions. Chem Lett 13:969–972

    Google Scholar 

  296. Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP (2005) Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol 16:3295–3305

    PubMed  CAS  Google Scholar 

  297. Turk MJ, Reddy JA, Chmielewski JA, Low PS (2002) Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim Biophys Acta 1559:56–68

    PubMed  CAS  Google Scholar 

  298. Umezawa F, Eto Y, Tokoro T, Ito F, Maekawa K (1985) Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher). Biochem Biophys Res Commun 127:663–667

    PubMed  CAS  Google Scholar 

  299. van Winden EC (2003) Freeze-drying of liposomes: theory and practice. Methods Enzymol 367:99–110

    PubMed  Google Scholar 

  300. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP (2005) ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res 22:2115–2120

    PubMed  CAS  Google Scholar 

  301. Verma DD, Hartner WC, Thakkar V, Levchenko TS, Torchilin VP (2007) Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res 24(11):2131–2137

    PubMed  CAS  Google Scholar 

  302. Verma DD, Levchenk T, Bernstein EA, Torchilin V (2004) ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model. In: 31st annual meeting of the Controlled Release Society, Honolulu 2004, Controlled Release Society, #572

    Google Scholar 

  303. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP (2006) ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J Drug Target 14:273–280

    PubMed  CAS  Google Scholar 

  304. Verma DD, Verma S, Blume G, Fahr A (2003) Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur J Pharm Biopharm 55:271–277

    PubMed  CAS  Google Scholar 

  305. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW (2004) In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51:1153–1162

    PubMed  CAS  Google Scholar 

  306. Vingerhoeds MH, Haisma HJ, Belliot SO, Smit RH, Crommelin DJ, Storm G (1996) Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm Res 13:604–610

    PubMed  CAS  Google Scholar 

  307. Vutla NB, Betageri GV, Banga AK (1996) Transdermal iontophoretic delivery of enkephalin formulated in liposomes. J Pharm Sci 85:5–8

    PubMed  CAS  Google Scholar 

  308. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P (2004) Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37–49

    PubMed  CAS  Google Scholar 

  309. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310–315

    PubMed  CAS  Google Scholar 

  310. Weissig VV, Babich J, Torchilin VV (2000) Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool. Colloids Surf B Biointerfaces 18:293–299

    PubMed  CAS  Google Scholar 

  311. Westcott KR, Hill RL (1985) Reconstitution of a porcine submaxillary gland beta-D-galactoside alpha 2–3 sialyltransferase into liposomes. J Biol Chem 260:13116–13121

    PubMed  CAS  Google Scholar 

  312. Whiteman KR, Subr V, Ulbrich K, Torchilin VP (2001) Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res 11:153–164

    PubMed  CAS  Google Scholar 

  313. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993–1001

    PubMed  CAS  Google Scholar 

  314. Woodle MC (1998) Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 32:139–152

    PubMed  CAS  Google Scholar 

  315. Woodle MC, Storm G (1998) Long circulating liposomes: old drugs, new therapeutics. Biotechnology intelligence unit. Springer, Berlin, 301 p

    Google Scholar 

  316. Wu ZH, Ping QN, Wei Y, Lai JM (2004) Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol Sin 25:966–972

    PubMed  CAS  Google Scholar 

  317. Xu GX, Xie XH, Liu FY, Zang DL, Zheng DS, Huang DJ, Huang MX (1990) Adenosine triphosphate liposomes: encapsulation and distribution studies. Pharm Res 7:553–557

    PubMed  CAS  Google Scholar 

  318. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1:337–346

    PubMed  CAS  Google Scholar 

  319. Yagi N, Naoi M, Sasaki H, Abe H, Konishi H, Arichi S (1982) Incorporation of enzyme into the brain by means of liposomes of novel composition. J Appl Biochem 4:121–125

    CAS  Google Scholar 

  320. Yamabe K, Kato Y, Onishi H, Machida Y (2003) Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J Control Release 89:429–436

    PubMed  CAS  Google Scholar 

  321. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–177

    PubMed  CAS  Google Scholar 

  322. Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, Kim DD (2007) Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 14:301–308

    PubMed  Google Scholar 

  323. Yang TZ, Wang XT, Yan XY, Zhang Q (2002) Phospholipid deformable vesicles for buccal delivery of insulin. Chem Pharm Bull (Tokyo) 50:749–753

    CAS  Google Scholar 

  324. Yerushalmi N, Arad A, Margalit R (1994) Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 313:267–273

    PubMed  CAS  Google Scholar 

  325. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7:1237–1245

    PubMed  CAS  Google Scholar 

  326. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352–3356

    PubMed  CAS  Google Scholar 

  327. Zajac-Kaye M, Ts’o PO (1984) DNAase I encapsulated in liposomes can induce neoplastic transformation of Syrian hamster embryo cells in culture. Cell 39:427–437

    PubMed  CAS  Google Scholar 

  328. Zalipsky S, Qazen M, Walker JA 2nd, Mullah N, Quinn YP, Huang SK (1999) New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 10:703–707

    PubMed  CAS  Google Scholar 

  329. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG (2007) Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 67:655–666

    PubMed  CAS  Google Scholar 

  330. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP (2006) siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 112:229–239

    PubMed  CAS  Google Scholar 

  331. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C (2007) In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 24:1193–1201

    PubMed  CAS  Google Scholar 

  332. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C (2007) In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 24:1193–1201

    PubMed  CAS  Google Scholar 

  333. Zheng J, Perkins G, Kirilova A, Allen C, Jaffray DA (2006) Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest Radiol 41:339–348

    PubMed  Google Scholar 

  334. Zhong ZR, Liu J, Deng Y, Zhang ZR, Song QG, Wei YX, He Q (2007) Preparation and characterization of a novel nonviral gene transfer system: procationic-liposome-protamine-DNA complexes. Drug Deliv 14:177–183

    PubMed  CAS  Google Scholar 

  335. Zhou F, Kraehenbuhl JP, Neutra MR (1995) Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 13:637–644

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 360 Huntington Avenue, Boston, MA, 02115, USA

    Vladimir Torchilin

Authors
  1. Vladimir Torchilin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladimir Torchilin .

Editor information

Editors and Affiliations

  1. Rue Maurice Schumann 3, Phalempin, 59133, France

    Juergen Siepmann

  2. , Department of Pharmaceutics, University of Minnesota, Harvard Street SE 308, Minneapolis, 55455, Minnesota, USA

    Ronald A. Siegel

  3. , School of Pharmacy, Griffith University, Parklands Drive 1, Southport, 4215, Queensland, Australia

    Michael J. Rathbone

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer US

About this chapter

Cite this chapter

Torchilin, V. (2012). Liposomes in Drug Delivery. In: Siepmann, J., Siegel, R., Rathbone, M. (eds) Fundamentals and Applications of Controlled Release Drug Delivery. Advances in Delivery Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0881-9_11

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation